(Q34530230)

2 August 2017

1 reference

title

The future prospects of pharmacogenetics in oral anticoagulation therapy (English)

1 reference

2 August 2017

1 reference

Munir Pirmohamed

2

0 references

author name string

Farhad Kamali

series ordinal

1

1 reference

PubMed ID

16722840

2 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

British Journal of Clinical Pharmacology

2 August 2017

1 reference

2 August 2017

61

1 reference

2 August 2017

746-751

1 reference

2 August 2017

6

1 reference

Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

The influence of ethnicity on warfarin dosage requirement

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Identification of the gene for vitamin K epoxide reductase

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Risk factors for bleeding in patients taking coumarins.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

CYP2C9 allelic variants: ethnic distribution and functional significance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Frequency of cytochrome P450 2C9 mutant alleles in a Korean population

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Factors determining the maintenance dose of warfarin in Chinese patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

The influence of age, liver size and enantiomer concentrations on warfarin requirements

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Effect of age upon the induction and maintenance of anticoagulation with warfarin.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Flexible induction dose regimen for warfarin and prediction of maintenance dose

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Aging and the anticoagulant response to warfarin therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Factors affecting the maintenance dose of warfarin

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Patient-specific factors predictive of warfarin dosage requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Warfarin dose adjustments based on CYP2C9 genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Racial background is a determinant factor in the maintenance dosage of warfarin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

VKORCI haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1885126

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics

9 December 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Anticoagulation of older patients: a need to modify current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2006.02679.X

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group

21 January 2018

1 reference

12 December 2020

Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

1 reference

12 December 2020

Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people

1 reference

12 December 2020

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

1 reference

12 December 2020

Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese

1 reference

12 December 2020

Initiating and Maintaining Patients on Warfarin Anticoagulation: The Importance of Monitoring

1 reference

12 December 2020

Vitamin K intake and sensitivity to warfarin in patients consuming regular diets

1 reference

12 December 2020

Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials

1 reference

12 December 2020

10.1111/J.1365-2125.2006.02679.X

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

PubMed ID

16722840